UCSF
Delve Bio, Broad Clinical Labs Partner for Metagenomic Infectious Disease Sequencing
Through the partnership, Delve Bio will leverage Broad Clinical Labs' sequencing capability to accelerate the commercialization of its metagenomic assay.
In addition to proving clinical utility, the startup will have to navigate issues of regulatory strategy, sequencing technology, and additional indications.
Delve Bio Raises $35M in Series A Financing to Develop Metagenomic Sequencing Diagnostics
The UCSF spinout's cofounders include Joe DeRisi and Charles Chiu, as well as Pardis Sabeti of Harvard University and the Broad Institute.
UCSF researchers developed a polygenic score for PSA production that may be able to help account for individual variation in PSA levels.
Abbott Test Can Be Used to Predict Death, Disability for Patients With TBI, Study Finds
The researchers studied the value of testing patients with traumatic brain injury for the GFAP and UCH-L1 markers using Abbott Labs' point-of-care i-STAT Alinity System.